dabrafenib: Clinical Trials

14 trials of dabrafenib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 recruiting, 2 active not recruiting, 1 not yet recruiting. 14 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 6, Recruiting 3, Active not recruiting 2, Not yet recruiting 1, Terminated 1, Unknown 1
Phase 23Recruiting 2, Not yet recruiting 1

Follow dabrafenib: new trials by email Literature Review of dabrafenib trials Research Report on dabrafenib

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm
Phase 2 / Phase 3RecruitingCancer Research UK302026-04-012026-08-17
Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
Dabrafenib and trametinib (combination) - Ameloblastoma
Phase 2 / Phase 3Not yet recruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University462025-03-012025-02-11
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Biospecimen Collection, Cabozantinib, Computed Tomography - Refractory Differentiated Thyroid Gland Carcinoma
Phase 3RecruitingECOG-ACRIN Cancer Research Group2642024-12-272026-11-16
Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma
Dabrafenib - Ameloblastoma
Phase 3UnknownShandong University102024-03-012024-02-20
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour
Phase 2 / Phase 3RecruitingCancer Research UK8252023-03-012026-07-01
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Dabrafenib, Trametinib, Trametinib Placebo - Differentiated Thyroid Cancer (DTC)
Phase 3Active not recruitingNovartis Pharmaceuticals1532021-11-152026-09-21
Molecular Profiling of Advanced Soft-tissue Sarcomas
Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma
Phase 3CompletedInstitut National de la Santé Et de la Recherche Médicale, France6032019-10-192026-04-29
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
Dabrafenib, Trametinib - Malignant Melanoma
Phase 3CompletedNovartis Pharmaceuticals5522018-08-292025-04-29
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
Spartalizumab, Placebo, Dabrafenib - Melanoma
Phase 3TerminatedNovartis Pharmaceuticals5682017-02-172025-09-18
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 3Active not recruitingNational Cancer Institute (NCI)2672015-09-082026-11-18
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
Dabrafenib, Trametinib, Placebos - Melanoma
Phase 3CompletedNovartis Pharmaceuticals8702013-01-082026-04-21
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Dabrafenib, Vemurafenib, Trametinib - Melanoma
Phase 3CompletedNovartis Pharmaceuticals7042012-06-042021-02-24
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Dabrafenib, Trametinib, Trametinib placebo - Melanoma
Phase 3CompletedNovartis Pharmaceuticals4232012-05-042021-02-17
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
GSK2118436, Dacarbazine (DTIC) - Cancer
Phase 3CompletedGlaxoSmithKline2512010-12-232017-10-04

Conditions studied

Melanoma (7)  ·  Neoplasms (5)  ·  Ameloblastoma (2)  ·  Hematologic Neoplasms (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms by Site (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Erdheim-Chester Disease (1)  ·  Fever (1)  ·  Gastrointestinal Neoplasms (1)  ·  Glioma (1)  ·  Histiocytosis, Langerhans-Cell (1)  ·  Laryngeal Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (6)  ·  Cancer Research UK (2)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  GlaxoSmithKline (1)  ·  Institut National de la Santé Et de la Recherche Médicale, France (1)  ·  National Cancer Institute (NCI) (1)  ·  Shandong University (1)  ·  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)

Countries

United States (8)  ·  Canada (7)  ·  France (7)  ·  United Kingdom (7)  ·  Argentina (6)  ·  Australia (6)  ·  Italy (6)  ·  Russia (6)  ·  Brazil (5)  ·  Germany (5)  ·  Netherlands (5)  ·  Poland (5)  ·  Spain (5)  ·  Sweden (5)  ·  Czechia (4)

Top investigators

Antoine Italiano (1)  ·  Lova Sun (1)  ·  Matthew Krebs (1)  ·  Matthew Krebs, Dr (1)  ·  Michael B Atkins (1)  ·  Qing Li (1)

Results publications

PMID 34225229, PMID 27864013, PMID 31166680, PMID 24408395, PMID 24769640, PMID 25265492, PMID 25399551, PMID 25411413, PMID 25794603, PMID 26037941, PMID 26040620, PMID 26433819, PMID 26446943, PMID 28891408, PMID 29784747, PMID 30343620, PMID 30928620, PMID 31864178, PMID 32007138, PMID 32713836, PMID 32877599, PMID 33020648, PMID 33587894, PMID 34740331, PMID 35030011, PMID 35042070, PMID 35728875, PMID 36166727, PMID 36653848, PMID 37966914, PMID 38899716, PMID 39274556, PMID 40250457, PMID 42442381, PMID 42585631

NIH funding

U10CA180820 (2), 2016 (1), 2017 (1), 2018 (1)